Risk Factors for Progressive Supranuclear Palsy (PSP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00431301
Recruitment Status : Completed
First Posted : February 5, 2007
Last Update Posted : April 10, 2017
National Institute on Aging (NIA)
Information provided by (Responsible Party):
University of Louisville

Brief Summary:
Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.

Condition or disease
Progressive Supranuclear Palsy

Detailed Description:
This proposal will determine: (1) if there is an association between PSP and specific genes of interest; (2) if there is an association between PSP and occupational and/or environmental chemical exposures functionally or structurally similar to known parkinsonian toxicants; and (3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Understanding the etiology of PSP may also help explain the causes of other related diseases such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the etiology of PSP.

Study Type : Observational
Actual Enrollment : 942 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Genetic and Environmental Risk Factors for PSP
Study Start Date : August 2006
Actual Primary Completion Date : February 2013
Actual Study Completion Date : June 2013

PSP Cases
Healthy Controls

Biospecimen Retention:   Samples With DNA
DNA will be used for genotyping specific genes of interest related to the disease.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with clinically diagnosed Progressive Supranuclear Palsy and healthy controls

Inclusion Criteria:

  • PSP patients able to visit one of the screening sites for diagnostic confirmation and able to participate in a one hour telephone interview

Exclusion Criteria:

  • No other major neurological disorders
  • Unable to communicate by telephone

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00431301

United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
United States, California
Los Angeles, California, United States, 90095-1759
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, Georgia
Emory College of Medicine
Atlanta, Georgia, United States, 30322
United States, Illinois
Rush University
Chicago, Illinois, United States, 60611
United States, Kansas
University of Kansas
Kansas City, Kansas, United States, 66160
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Ohio
Case Western University
Cleveland, Ohio, United States, 44106
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5T 2S8
Sponsors and Collaborators
University of Louisville
National Institute on Aging (NIA)
Principal Investigator: Irene Litvan, M.D. University of Louisville

Additional Information:
Responsible Party: University of Louisville Identifier: NCT00431301     History of Changes
Other Study ID Numbers: 1R01AG024040-01A2 ( U.S. NIH Grant/Contract )
1R01AG024040-01A2 ( U.S. NIH Grant/Contract )
First Posted: February 5, 2007    Key Record Dates
Last Update Posted: April 10, 2017
Last Verified: April 2017

Keywords provided by University of Louisville:
Progressive Supranuclear Palsy
Neurodegenerative Disease
Movement Disorders
Atypical Parkinsonism
Parkinson Plus

Additional relevant MeSH terms:
Ocular Motility Disorders
Supranuclear Palsy, Progressive
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Cranial Nerve Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Eye Diseases
Signs and Symptoms